Lloyd Curtis

Risk of Myocardial Infarction and Abacavir Therapy: No Increased Risk Across 52 GlaxoSmithKline-Sponsored Clinical Trials in Adult Subjects

Cindy Brothers, Jaime E. Hernández, Amy Cutrell et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2009 · 182 citations

Medicine, Cardiology, Pharmacology +15

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng et al. · Clinical Infectious Diseases · 2022 · 170 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +15

Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

W. Garrett Nichols, H. M. Steel, Tab Bonny et al. · Antimicrobial Agents and Chemotherapy · 2007 · 146 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Psychiatric Symptoms in Patients Receiving Dolutegravir

Anna Fettiplace, Chris Stainsby, Alan Winston et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2016 · 101 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era

Stephanie A. Ruderman, Heidi M. Crane, Robin M. Nance et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2020 · 81 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacotherapy +16